ALZINOVA AB
Research ALZINOVA AB (78D) on Bullrun: market cap EUR 3.83M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker78D
- ExchangeF
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 3.83M
- Financial periodQ4 2025
- Net income-EUR 5.89M
- Free cash flow-EUR 166.00K
Valuation Snapshot
latest market cap is EUR 3.83M.
About ALZINOVA AB
Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. The company's lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b clinical trial. It also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease;
Frequently asked questions
What is ALZINOVA AB's market cap?
ALZINOVA AB's market capitalization is EUR 3.83M.
What does ALZINOVA AB do?
Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. The company's lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b clinical trial.